Search by Drug Name, NDC or Jcode

    Internal Navigation

    HCPCS Details

    HCPC J2350
    Short Description Injection, ocrelizumab, 1 mg
    Long Description Injection, ocrelizumab, 1 mg
    Pricing indicator 51
    Coverage code C
    ASC payment group code YY
    BETOS2 code O1E
    Action code N
    Type of service 1
    Effective date 2018-01-01
    Date Added 2018-01-01

    HCPCS/NDC Cross-Walk

    NDC HCPC Description Drug Name Labeler Name HCPCS Dosage PKG Size PKG QTY Bill Units Bill Units PKG
    50242015001 J2350 Injection, ocrelizumab, 1 mg OCREVUS GENENTECH, INC. 1 MG 10 1 300 300
    The ASP crosswalks are maintained by the Division of Data Analysis and Market Based Pricing to support ASP-based Medicare Part B payments only. The crosswalks are intended to help the public (including entities that submit manufacturer ASP data and providers who bill for drugs) understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes. The crosswalks are not intended to be a comprehensive list of all drugs/NDCs available in the United States. The NDC to HCPCS Crosswalk also includes information on the NDC package size and the number of billable units (as defined by the HCPCS code descriptor). Comments on the file may be sent to [email protected].

    HCPCS Billing Calculator

    Dosage given to patient (per dose)
    HCPCS Dosage 1 MG
    HCPCS/CPT Billing Units 1
    Total doses ordered
    Billing Units 1

    Drug Details

    • Ocrelizumab injection is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) including:

      • primary-progressive forms (symptoms gradually become worse over time) of MS,

      • clinically isolated syndrome (CIS; nerve symptom episodes that last at least 24 hours),

      • relapsing-remitting forms (course of disease where symptoms flare up from time to time), or

      • secondary progressive forms (course of disease where relapses occur more often).

    • Ocrelizumab in a class of medications called monoclonal antibodies. It works by stopping certain cells of the immune system from causing damage.